Related Experiment Video
Updated: Jun 5, 2025

Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice
Published on: February 15, 2019
Safety and Tolerability of Intravenous Lidocaine Infusions as Opioid Adjunct for Children Hospitalized With Sickle
Ugochukwu Agbakwuru1, Jacob D AuBuchon2, Bobi Toebe2
1Aflac Cancer and Blood Disorder Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
Insights
Intravenous lidocaine infusions as an adjunct to opioids for sickle cell disease (SCD) vaso-occlusive episodes (VOE) showed no serious toxicities in pediatric patients. Most recipients opted for repeat treatments, suggesting good tolerability.
Area of Science:
- Pediatric Hematology
- Pain Management
- Pharmacology
Background:
- Opioids are standard for sickle cell disease (SCD) vaso-occlusive episode (VOE) pain but carry side effects.
- Non-opioid adjuvants may offer pain relief with improved safety profiles.
- Intravenous lidocaine is explored as a potential adjunctive therapy.
Purpose of the Study:
- To retrospectively investigate the safety and tolerability of intravenous lidocaine infusions.
- To assess lidocaine's use as an adjunct to opioids in pediatric patients during VOE hospitalizations.
Main Methods:
- Retrospective analysis of pediatric patients hospitalized for VOE.
- Data collected over a 2-year period on lidocaine administration and patient outcomes.
- Evaluation of toxicity, repeat treatment choices, and hospitalization duration.
Main Results:
- Lidocaine was administered in 64.6% of 260 admissions.
- No serious toxicities were reported.
- 82.2% of recipients chose lidocaine for subsequent admissions, indicating good tolerability.
- Lidocaine infusions were associated with longer hospitalizations, possibly due to selection bias.
Conclusions:
- Intravenous lidocaine appears safe and well-tolerated as an adjunct to opioids for pediatric VOE.
- Further prospective studies are needed to confirm the efficacy of adjuvant lidocaine infusions in VOE management.
Abstract:
Sickle cell disease (SCD) vaso-occlusive episode (VOE) pain is treated with opioids, and non-opioid adjuvants may reduce pain severity without opioid side effects. We retrospectively investigated the safety and tolerability of intravenous lidocaine infusions as an adjunct to opioids in children and adolescents during VOE hospitalizations. In 2 years, lidocaine was administered in 64.6% of 260 admissions. There were no serious toxicities; overall, 82.2% of recipients chose to receive lidocaine during subsequent admissions. Lidocaine infusions were associated with longer hospitalizations, potentially reflecting selection bias. The efficacy of adjuvant lidocaine infusions during VOE should be studied prospectively.
More Related Videos
06:04Objective Nociceptive Assessment in Ventilated ICU Patients: A Feasibility Study Using Pupillometry and the Nociceptive Flexion Reflex
Published on: July 4, 2018
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Related Concept Videos
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Common Agents and Their Applications
Cocaine is an ester of benzoic acid and methylecgogine. It is used to anesthetize and vasoconstrict locally. Currently, it is used primarily for topical applications. It is beneficial for surgeries on the upper respiratory tract, providing anesthesia and shrinking the mucosa. Cocaine in the form of cocaine hydrochloride is...
Local Anesthetics: Clinical Application as Spinal Anesthesia
Parenteral Anesthetics: Overview
Local Anesthetics: Pharmacokinetics